Aventis Behring Spearheads Educational Initiative to Improve Treatment of Hemophilia in Developing Countries.Business Editors/Health/Medical Writers KING OF PRUSSIA King of Prussia, industrialized suburban area (1990 pop. 18,406), Montgomery co., SE Pa. It has glass and steel fabricating, food processing, printing and publishing, and varied manufacturing (textiles, liquified petroleum gas, water-treatment and electrical , Pa.--(BUSINESS WIRE)--Oct. 20, 2003 The Children's Hospital of Philadelphia The Children's Hospital of Philadelphia is one of the largest and oldest children's hospitals in the world. "CHOP" has been ranked as the best children's hospital in the United States by U.S. News & World Report and Child Magazine in recent years. Hosts Training Session For Visiting International Hematologists Aventis Behring L.L.C., (NYSE NYSE See: New York Stock Exchange : AVE) a global leader in the plasma protein plasma protein n. Any of the various dissolved proteins of blood plasma, including antibodies and blood-clotting proteins, that act by holding fluid in blood vessels by osmosis. industry, welcomed a group of international hematologists to The Children's Hospital of Philadelphia (CHOP) today. The doctors are participants in The Physicians Development in Hemophilia Care Project, a training initiative that is part of a larger educational program sponsored by Aventis Behring that seeks to improve the treatment of hemophilia within medical communities of developing countries. For five days, doctors and scientists from Taiwan, Argentina, Hungary, Slovakia, Mexico and Turkey will attend courses instructed by some of the leading hematologists in the U.S. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Javier Gomez-Olvera, Hemophilia Marketing Manager, Developing Countries, Aventis Behring, the course is designed to present some of latest scientific and methodological advances in hematology and especially in coagulation disorders Coagulation Disorders Definition Coagulation disorders deal with disruption of the body's ability to control blood clotting. The most commonly known coagulation disorder is hemophilia, a condition in which patients bleed for long periods of time before . "Each year, the brightest and most promising hematologists in these countries are invited by Aventis Behring to participate in this program," said Mr. Gomez-Olvera. "These doctors attend this session with the goal of returning to their respective countries as trainers, sharing the information they have received through this program with fellow doctors, nurses, health professionals and patients." The program is intended to be comprehensive, featuring courses addressing the genetics of hemophilia, research methods, physical therapy, therapy in clinical settings, home therapy, and new challenges in the twenty-first century. The participating physicians will also have the opportunity to exchange information amongst themselves, tour laboratories at the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. , and visit Presbyterian Medical Center to gain practical, hands-on experience. According to Mr. Gomez-Olvera, the combination of education and experience should prove invaluable to the visiting hematologists. The 3rd Physicians Development in Clinical Hemophilia Care Project is just one of eleven ongoing initiatives that Aventis Behring is sponsoring in developing countries. Other initiatives include: The Nurses Leadership Project and Aventis Behring Camp Support - In this program, selected nurses from developing countries receive the most updated information on the practical aspects of the treatment of hemophilia. After these sessions are completed, the participating nurses will apply this new information in a camp for people with hemophilia. The Safety Odyssey - In an effort to allay concerns of local governments and to demonstrate that there is an adequate supply of safe and effective plasma-derived therapies for those in need, Aventis Behring welcomes leading health officials from developing countries to tour the company's facilities and to observe the numerous rigorous processes Aventis Behring uses in its continuous efforts to produce safe products. The Wall Library - Aventis Behring has translated and adapted several educational books on hemophilia for many countries, including Turkey, Brazil, Mexico, Argentina, Taiwan, China, Korea, and Indonesia. The books are displayed in an acrylic wall system and are available in selected hemophilia centers. The Aventis Behring Grant - Grants awarded by Aventis Behring to people in countries in Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. , the Middle East and South Asia that submit innovative plans for improving the quality of life for people with hemophilia. Pharmacoeconomic Studies - Studies designed to demonstrate the costs/benefits results of treating people with hemophilia with inactivated inactivated rendered inactive; the activity is destroyed. inactivated viruses treated so that they are no longer able to produce evidence of growth or damaging effect on tissue. plasma concentrates at home versus concentrates or cryoprecipitate cryoprecipitate /cryo·pre·cip·i·tate/ (-pre-sip´i-tat) any precipitate that results from cooling, sometimes specifically the one rich in coagulation factor VIII obtained from cooling of blood plasma. in the hospital. "As an industry leader, it is our responsibility to strive to ensure that patients in developing countries can benefit from the latest treatments and cutting-edge advances in the field," said Stephen Farrell, Vice-President, Hemophilia Business Unit, Aventis Behring. "We have committed ourselves to aiding people with hemophilia around the globe. With the help of local hematologists, nurses and patients, we will remain diligent in our efforts to ensure that an increasing number of people with hemophilia receive treatment for their condition." About Hemophilia According to the World Federation of Hemophilia, more than 400,000 people in the world have hemophilia A hemophilia A n. Hemophilia due to deficiency of factor VIII, characterized by prolonged clotting time, decreased formation of thromboplastin, and diminished conversion of prothrombin. or B, 115,000 patients have been identified and more than 285,000 remain undiagnosed and /or untreated, most of whom live in developing countries. Hemophilia A & B are inherited bleeding disorders caused by a lack or absence of one of the proteins in blood (called factors) that control bleeding. Hemophilia A is caused by a deficiency of factor VIII factor VIII n. A factor in the clotting of blood, a deficiency of which is associated with hemophilia A. Also called antihemophilic factor, antihemophilic globulin, antihemophilic globulin A, , and hemophilia B hemophilia B n. A clotting disorder of blood resembling hemophilia A, caused by hereditary deficiency of factor IX. Also called Christmas disease. is caused by a deficiency of factor IX. People with hemophilia may experience spontaneous bleeding, and even minor injuries may present considerable danger. Both types of hemophilia are characterized by an onset of symptoms very early in childhood. About Aventis Behring Aventis Behring, part of the Aventis family of companies, is a global leader in the plasma protein industry, providing a wide range of innovative and high-quality medicines to patients worldwide. Aventis Behring is dedicated to research and development in the area of human blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. as well as in emerging technologies. For more information about Aventis Behring, please visit: www.AventisBehring.com. Aventis (NYSE: AVE) is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2002, Aventis generated sales of EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 17.6 billion, invested EUR 3.1 billion in research and development and employed approximately 71,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com. Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -"Document de Reference"- on file with the "Commission des Operations de Bourse bourse (b  rs), term applied to a European stock exchange. The first international bourse was established in Antwerp in the 16th cent. " in France.
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion